1. Scrip
  2. >>Business

Novartis Culls Pipeline As ‘Pure-Play’ Drive Progresses

Removes PD-1 Inhibitor, Adds To Radioligand Pipeline

 
• By Andrew McConaghie

The Swiss company has raised its 2023 forecast thanks to stronger Q1 sales, but its transformation towards a more ‘pure-play’ pharma company is still a work in progress.

Novartis NIBR Cambridge, MA

Novartis has followed through on a pledge to streamline its R&D and commercial focus, with the company announcing that it has cut 10% of its pipeline in the first quarter.

The update came along with better-than-expected results for the period, which allowed Swiss big pharma company to raise its full-year...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.